Supportive Care in Cancer

, Volume 20, Issue 3, pp 483–488

Clinical features and outcomes of Staphylococcus aureus infections in non-neutropenic cancer patients

  • Cheol-In Kang
  • Jae-Hoon Song
  • Kwan Soo Ko
  • Doo Ryeon Chung
  • Kyong Ran Peck
  • Asian Network for Surveillance of Resistant Pathogens (ANSORP) Study Group
Original Article

DOI: 10.1007/s00520-011-1100-5

Cite this article as:
Kang, CI., Song, JH., Ko, K.S. et al. Support Care Cancer (2012) 20: 483. doi:10.1007/s00520-011-1100-5

Abstract

Goal of work

This study was performed to evaluate the clinical features and outcomes of Staphylococcus aureus infection in non-neutropenic cancer patients.

Materials and methods

From the database of a surveillance study for S. aureus infections, the data regarding S. aureus infections in non-neutropenic cancer patients were analyzed.

Main results

Of 649 non-neutropenic cancer patients with S. aureus infections, 156 (24.0%) had a central venous catheter and 176 (27.1%) had an indwelling urinary catheter. The prevalence of methicillin-resistant S. aureus (MRSA) infections was 54.7% (355 out of 649). As for types of infection, skin and soft tissue infections were the most common (n = 173, 26.7%), followed by pneumonia (n = 165, 25.4%) and primary bacteremia (n = 91; 14.0%). Overall, the 30-day mortality rate was 28.2% (124 out of 440), 34.1% (73 out of 214) in MRSA group, and 22.6% (51 out of 226) in methicillin-sensitive S. aureus group (P = 0.007). When outcomes according to the types of infection were evaluated, the mortality rates were 49.5% (53 out of 107) for pneumonia and 41.2% (49 out of 119) for bacteremia. Multivariate analysis showed that pneumonia, concomitant bacteremia, comorbid liver disease, and intubated state with ICU care were independent risk factors associated with 30-day mortality.

Conclusion

Our study demonstrated that S. aureus infections in cancer patients are serious clinical conditions with high mortality rates, even in non-neutropenic patients.

Keywords

Staphylococcus aureus Risk factors Treatment outcome Infection Neoplasms 

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Cheol-In Kang
    • 1
  • Jae-Hoon Song
    • 1
    • 3
  • Kwan Soo Ko
    • 2
  • Doo Ryeon Chung
    • 1
  • Kyong Ran Peck
    • 1
  • Asian Network for Surveillance of Resistant Pathogens (ANSORP) Study Group
  1. 1.Division of Infectious Diseases, Samsung Medical CenterSungkyunkwan University School of MedicineSeoulRepublic of Korea
  2. 2.Department of Molecular Cell BiologySungkyunkwan University School of MedicineSuwonRepublic of Korea
  3. 3.Asia Pacific Foundation for Infectious DiseasesSeoulRepublic of Korea

Personalised recommendations